CEDOBACT

CEDOBACT
Cefpodoxime Proxetil 50 mg + Clavulanic Acid 31.25 mg

THE NEED FOR A BETA-LACTAM + BETA LACTAMASE INHIBITOR COMBINATION

Among different antibiotics, beta lactam antibiotics account for approximately 50% of global antibiotic
consumption because of their proven efficacy and safety. It is well documented fact that bacterial resistance
to this group of antibiotic increased parallely with increasing use of these antibiotics. Strategy for overcoming
bacterial resistance with newer cephalosporins has been successfully employed as it was possible to modify
structure of a cephalosporin nucleus easily to confer an additional advantage. However, it has become clear
that such attempts have been not only short lived but has created an alarming situation that currently
available antibiotics are not adequate to control infection due to resistant bacteria.

Reintroduction of currently available penicillins and cephalosporins with other agents such as beta lactamase
inhibitors is an attractive preposition for many reasons;

1) Well established safety and efficacy profile
2) Production of beta lactamase is the most common mechanism of resistance to beta lactam antibiotics,
especially in gram negative bacteria
3) Convenience of use, and more essentially an understanding that using such combination empirically may
help in not only overcome therapeutic failures due to resistant bacteria but will also delay resistance
development in susceptible bacteria
4) Minimize use of newer antibacterials so that they remain effective antibacterial for specific use

.